Unoprostone Explained

Unoprostone (INN) is a prostaglandin analogue. Its isopropyl ester, unoprostone isopropyl, was marketed under the trade name Rescula for the management of open-angle glaucoma and ocular hypertension.^[1]

It was approved by the Food and Drug Administration in 2000.^[2]

In 2009, Sucampo Pharmaceuticals acquired the rights to the drug in the U.S. and Canada.^[3]

In 2015, the drug was discontinued in the U.S.

Notes and References

1. Fung DS, Whitson JT . An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy . Clinical Ophthalmology . Auckland, N.Z. . 8 . 543–54 . 2014 . 24648719 . 3958522 . 10.2147/OPTH.S41562 . free .
2. News: Drug Approval Package . Food and Drug Administration.
3. Sucampo Pharmaceuticals, Inc. Acquires Rights to Rescula for U.S. and Canada . . April 24, 2009.